7.2 Screening for Drug Therapy Problems & Pharmacist Referral Triggers
Key Takeaways
The 7 classic Drug Therapy Problem (DTP) categories (unnecessary therapy, additional therapy needed, ineffective drug, dosage too low, adverse drug reaction, dosage too high, non-adherence) form the standard Canadian clinical triage taxonomy.
Registered Pharmacy Technicians carry independent professional responsibility for screening prescriptions for technical and clinical red flags, but must refer all suspected DTPs to the pharmacist without offering clinical advice to the patient or prescriber.
Severe therapeutic duplications—such as concurrent prescriptions for two distinct NSAIDs, multiple ACE inhibitors, or simultaneous brand and generic dispensing—represent critical safety alerts requiring immediate escalation.
High-alert drug interactions (e.g., warfarin with antimicrobials/NSAIDs, weekly oral methotrexate with daily dosing errors, or clarithromycin with simvastatin) demand immediate quarantine and pharmacist review.
Technicians utilize the SBAR (Situation, Background, Assessment, Recommendation) framework to communicate screening alerts objectively to the pharmacist while maintaining professional scope boundaries.
Screening for Drug Therapy Problems & Pharmacist Referral Triggers
Exam Tip: In Canadian pharmacy practice, Registered Pharmacy Technicians act as the first line of defense in intercepting medication safety hazards during order entry and technical dispensing. On the PEBC exam, candidates must demonstrate keen vigilance in recognizing potential Drug Therapy Problems (DTPs)—such as therapeutic duplication, major drug interactions, disease contraindications, and dosing deviations. Crucially, exam questions test your understanding of professional scope: technicians identify and flag potential problems and refer them to the pharmacist, but never provide clinical counsel to patients or independently negotiate therapy alterations with prescribers.
The Philosophy & Architecture of Drug Therapy Problems
In Canadian pharmacy practice, patient care is structured around the identification, prevention, and resolution of Drug Therapy Problems (DTPs), a concept originally formulated in pharmaceutical care theory by Cipolle, Strand, and Morley. A Drug Therapy Problem is defined as:
Any undesirable event experienced by a patient that involves, or is suspected to involve, drug therapy, and that actually or potentially interferes with achieving desired therapeutic goals.
The 7 Classic DTP Categories
Under Canadian practice competencies, every medication-related issue can be classified into one of seven standardized categories organized under four core patient needs: Indication, Effectiveness, Safety, and Adherence.
| Patient Need | DTP Category | Clinical Definition | Common Clinical Example | Technician Screening Red Flag |
|---|---|---|---|---|
| Indication | 1. Unnecessary Drug Therapy | Patient is receiving a medication without a valid clinical indication, duplicate therapy exists, or the condition is better managed non-pharmacologically. | Patient taking both brand-name Norvasc and generic amlodipine concurrently, or taking two oral NSAIDs simultaneously. | Dispense history reveals duplicate active chemical entities or concurrent drugs in identical therapeutic classes. |
| Indication | 2. Requires Additional Drug Therapy | Patient has an untreated medical condition requiring pharmacotherapy, requires synergistic therapy, or needs preventative/prophylactic therapy. | Patient on long-term systemic oral corticosteroids without bone protection (calcium/vitamin D/bisphosphonate), or chronic opioid therapy without a bowel regimen. | Profile shows high-risk drug initiated without standard guideline-mandated prophylactic co-therapy. |
| Effectiveness | 3. Ineffective Drug | Drug prescribed is not the most effective agent for the medical condition, the condition is refractory, or the dosage form is inappropriate. | Patient with severe diabetic gastroparesis prescribed standard oral delayed-release tablets that fail to absorb properly. | Rapid sequence of refills or frequent switches between first-line agents within the same class. |
| Effectiveness | 4. Dosage Too Low | Drug dose is insufficient to produce the desired clinical outcome, dosing interval is too infrequent, or duration is too short. | Adult with severe strep throat prescribed amoxicillin 250 mg once daily instead of standard therapeutic dosing (e.g., 500 mg TID). | Prescription dose falls substantially below Canadian Compendium of Pharmaceuticals and Specialties (CPS) standard dosing ranges. |
| Safety | 5. Adverse Drug Reaction (ADR) | Patient experiences an undesirable adverse reaction, allergic response, toxic effect, or clinically significant drug-drug/drug-disease interaction. | Patient prescribed clarithromycin while taking high-dose simvastatin, precipitating rhabdomyolysis and acute renal failure. | Pharmacy management system triggers a major (Level 1 / Severe) interaction alert or documented allergy warning. |
| Safety | 6. Dosage Too High | Drug dose is excessive, dosing frequency is too frequent, or duration is too long for the patient's age, weight, or renal clearance. | Patient with eGFR of 20 mL/min prescribed standard full-dose nitrofurantoin (macrobid) or full-dose enoxaparin. | Calculated dose exceeds maximum established daily limits or lacks required renal dose reduction. |
| Adherence | 7. Non-Adherence / Non-Compliance | Patient is unable or unwilling to take the medication as prescribed due to cost, complex regimen, swallowing difficulty, or side effect fears. | Elderly patient filling chronic antihypertensive prescription every 90 days for a 30-day supply (PDC < 50%). | Refill records show severe tardiness, low Proportion of Days Covered (PDC), or patient expresses inability to afford copay. |
Screening Red Flags for Pharmacy Technicians
When inputting or technically verifying prescription orders, pharmacy technicians must maintain active screening vigilance. Several critical clinical scenarios require immediate intervention:
┌────────────────────────────────────────────────────────────────────────┐
│ Critical Red Flags Mandating Pharmacist Escalation │
├────────────────────────────────────────────────────────────────────────┤
│ 1. Therapeutic Duplication (e.g., Two NSAIDs, Brand + Generic) │
├────────────────────────────────────────────────────────────────────────┤
│ 2. High-Alert Drug Interactions (e.g., Warfarin + NSAID/Cipro) │
├────────────────────────────────────────────────────────────────────────┤
│ 3. Severe Disease Contraindications (e.g., Beta-blocker + Asthma) │
├────────────────────────────────────────────────────────────────────────┤
│ 4. Lethal Scheduling Errors (e.g., Oral Methotrexate prescribed DAILY) │
├────────────────────────────────────────────────────────────────────────┤
│ 5. Excessive Doses or Unadjusted Renal Clearance Regimens │
└────────────────────────────────────────────────────────────────────────┘
1. Therapeutic Duplications
- Multiple NSAIDs: Co-prescribing celecoxib with naproxen or ibuprofen. Combining two NSAIDs adds little or no extra pain relief but substantially raises the risk of gastrointestinal ulceration and bleeding, acute kidney injury and platelet dysfunction.
- Dual Renin-Angiotensin System Blockade: Co-prescribing an Angiotensin-Converting Enzyme (ACE) inhibitor (e.g., ramipril, perindopril) with an Angiotensin Receptor Blocker (ARB; e.g., candesartan, valsartan). Major clinical trials demonstrate no mortality benefit, accompanied by significant increases in severe hyperkalemia, syncope, and acute kidney injury.
- Brand and Generic Co-Dispensing: Occurs when a prescriber issues a prescription using a brand name (e.g., Lipitor, Synthroid) while the patient profile already contains an active prescription for the generic entity (atorvastatin, levothyroxine). If both are filled, the patient risks acute toxicity from a doubled dose.
2. Major High-Alert Drug-Drug Interactions (DDIs)
- Warfarin + Broad-Spectrum Antibiotics (e.g., Metronidazole, Ciprofloxacin, Trimethoprim-Sulfamethoxazole [TMP-SMX]): Some antibiotics inhibit warfarin's metabolism (metronidazole and TMP-SMX inhibit CYP2C9; ciprofloxacin inhibits CYP1A2), and broad-spectrum antibiotics can also reduce vitamin K-producing gut bacteria. The result can be a rapid, unpredictable rise in the International Normalized Ratio (INR) and serious bleeding.
- Oral Methotrexate + NSAIDs: In patients taking once-weekly low-dose oral methotrexate for rheumatoid arthritis or psoriasis, NSAIDs (e.g., naproxen, celecoxib) compete for renal organic anion transporters, reducing methotrexate tubular clearance. The resulting accumulation causes severe pancytopenia, bone marrow suppression, liver toxicity, and fatal mucositis.
- Macrolide Antibiotics (Clarithromycin, Erythromycin) + CYP3A4-Metabolized Statins (Simvastatin, Atorvastatin): Clarithromycin is a potent mechanism-based inhibitor of CYP3A4. Co-administration causes dramatic statin accumulation, triggering extensive skeletal muscle breakdown (rhabdomyolysis), myoglobinuria, and acute renal failure. (Note: Azithromycin does not inhibit CYP3A4 and carries minimal risk).
- Potassium-Sparing Diuretics (Spironolactone, Eplerenone) + ACE Inhibitors / ARBs + Potassium Supplements: Concurrent use markedly impairs renal potassium excretion, precipitating life-threatening hyperkalemia () and fatal cardiac arrhythmias.
- Serotonergic Combinations (SSRIs/SNRIs + Tramadol, Linezolid, Triptans, or St. John's Wort): Concomitant use precipitates central and peripheral serotonin overload (Serotonin Syndrome), manifested by tremor, clonus, hyperreflexia, autonomic instability, hyperthermia, and delirium.
3. Drug-Condition & Drug-Disease Contraindications
- Non-Selective Beta-Blockers in Reactive Airway Disease: Non-selective beta-blockers (e.g., propranolol, nadolol, carvedilol, timolol eye drops) block pulmonary receptors, triggering severe bronchoconstriction and fatal status asthmaticus in patients with asthma.
- Oral Sympathomimetic Decongestants in Hypertension & Glaucoma: Pseudoephedrine and phenylephrine stimulate vascular receptors, inducing peripheral vasoconstriction. In patients with uncontrolled hypertension, they cause acute hypertensive crises; in patients with narrow-angle glaucoma, they induce pupillary mydriasis, triggering acute angle closure.
- Systemic NSAIDs in Chronic Kidney Disease (CKD) & Heart Failure: NSAIDs block renal prostaglandin synthesis (), which is required to maintain afferent arteriolar vasodilation. In patients with compromised renal perfusion (CKD, heart failure, cirrhosis), NSAIDs cause acute afferent constriction, precipitating acute renal failure and massive sodium/water retention that exacerbates congestive heart failure.
- Anticholinergic Agents in the Elderly & BPH: Anticholinergics (e.g., oxybutynin, tolterodine, tricyclic antidepressants, diphenhydramine, dimenhydrinate) block muscarinic receptors. In elderly patients, they cause cognitive decline, delirium, blurred vision, and fall-related fractures. In men with benign prostatic hyperplasia (BPH), they paralyze detrusor muscle contraction, causing acute urinary retention.
4. Significant Dose Deviations & Lethal Frequency Errors
- Daily vs. Weekly Methotrexate: The single most notorious dosing tragedy in Canadian ambulatory pharmacy involves oral methotrexate. When prescribed for autoimmune disorders (rheumatoid arthritis, psoriasis), methotrexate is administered ONCE WEEKLY. If a prescription is inadvertently written, entered, or dispensed as ONCE DAILY, severe toxicity develops within 7 to 10 days, resulting in fatal bone marrow suppression and gastrointestinal hemorrhage. Any prescription for daily oral methotrexate represents a critical emergency stop.
- Pediatric Dose Calculations: Children have immature hepatic and renal clearance pathways. Any pediatric dose that deviates from standard reference ranges (e.g., amoxicillin or acetaminophen single doses ) must be immediately halted.
Professional Scope Boundaries & Communication Protocols
When a pharmacy management system triggers a major clinical interaction alert or when a technician uncovers a potential DTP during data verification, strict scope protocols dictate how the technician must respond.
Scope of Practice Boundaries
┌────────────────────────────────────────────────────────────────────────┐
│ Technician Action Decision Rule │
├────────────────────────────────────────────────────────────────────────┤
│ IF an issue involves: │
│ • Choosing between alternative drug therapies │
│ • Evaluating whether a clinical interaction is tolerable │
│ • Deciding to alter a dose, frequency, or duration │
│ • Counseling the patient on potential side effects or safety │
│ • Calling the prescriber to recommend a clinical therapy substitution │
│ │
│ THEN: It is EXCLUSIVELY within the PHARMACIST'S scope of practice. │
│ Technicians MUST NOT perform these clinical actions independently. │
└────────────────────────────────────────────────────────────────────────┘
Communicating with the Pharmacist: The SBAR Framework
Technicians should present identified DTP flags to the clinical pharmacist using the structured SBAR communication model:
- Situation (S): State the immediate issue concisely.
"I am inputting a new prescription for Mrs. Henderson for celecoxib 200 mg daily, but her profile shows she picked up a 90-day supply of naproxen 500 mg BID just two weeks ago." - Background (B): Provide relevant patient and profile context.
"Both prescriptions are written by different physicians—Dr. Patel (her family doctor) wrote the naproxen, but Dr. Chen (an orthopedic surgeon) wrote the celecoxib today." - Assessment (A): State the technical screening observation objectively without diagnosing or prescribing.
"This appears to be a therapeutic duplication involving two systemic NSAIDs, which creates an elevated risk for gastrointestinal bleeding and renal impairment." - Recommendation / Referral (R): Hand over the case for clinical resolution.
"I have placed the prescription in the pharmacist review queue and flagged the profile for your clinical assessment and prescriber follow-up before dispensing."
Professional Communication with the Patient
When a patient is waiting at the prescription counter and a DTP is detected, technicians must use calm, reassuring, and professional language that maintains patient trust in the healthcare team.
- Acceptable Scripting: "Mr. Smith, our dispensing system has flagged a safety note regarding your new prescription and one of your existing medications. I have handed your file to our pharmacist, Sarah, who is currently reviewing your profile to ensure everything is completely safe before we prepare your medication. She will be speaking with you directly in just a few minutes."
- Unacceptable Scripting: "Your doctor made a dangerous mistake and prescribed a toxic dose" or "You can't take this because it will cause stomach bleeding." Such statements trigger unwarranted panic, undermine the prescriber-patient relationship, and cross into clinical evaluation.
A community pharmacy technician processes a new prescription for celecoxib 200 mg orally once daily for a 68-year-old patient. Upon reviewing the patient's active medication record, the technician notes that the patient received a 30-day supply of naproxen 500 mg orally twice daily just five days ago from the same pharmacy. What Drug Therapy Problem (DTP) category does this represent, and what is the technician's correct action?
Dosage Too Low; the technician should increase the celecoxib dose to 400 mg daily to compensate for the naproxen.
Requires Additional Drug Therapy; the technician should dispense an OTC antacid alongside both prescriptions without notifying the pharmacist.
Non-Adherence; the technician should counsel the patient to alternate between the two medications on odd and even days.
Unnecessary Drug Therapy (Therapeutic Duplication); the technician must immediately halt processing and refer the case to the pharmacist for clinical assessment.
A pharmacy technician in an outpatient clinic receives a new electronic prescription for oral methotrexate 15 mg PO once daily for a 45-year-old patient diagnosed with rheumatoid arthritis. What critical safety red flag must the technician immediately identify?
Methotrexate for non-oncologic autoimmune indications must be dosed ONCE WEEKLY; daily administration leads to fatal bone marrow suppression and acute toxicity.
Methotrexate cannot be taken orally and must exclusively be administered by deep intramuscular injection.
Methotrexate is contraindicated in female patients under 65 years of age due to cardiovascular stroke risks.
The prescribed dose of 15 mg is far below the minimum effective adult dose of 150 mg daily.
While entering a new prescription for clarithromycin 500 mg PO BID for an acute respiratory infection, the pharmacy management software triggers a severe (Level 1) interaction alert indicating that the patient has an active profile for atorvastatin 80 mg PO daily. What is the most appropriate action for the registered pharmacy technician?
Override the software interaction alert independently, as computerized alerts are routinely ignored in high-volume dispensaries.
Call the prescribing physician immediately and order them to switch the patient from clarithromycin to azithromycin.
Flag the high-risk interaction, document the relevant dispensing details, and refer the file to the pharmacist using the SBAR technique for clinical intervention.
Inform the patient at the pick-up counter that they must permanently discontinue their cholesterol medication because it is incompatible with antibiotics.
Sections you finish are checked off in the contents.